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Abstract: Epidemiological and biological evidence indicate a causal relationship between the
presence of proliferative atrophic lesions (PAH), the development of PIN and prostate
cancer. Inflammatory and atrophic lesions of the prostate are widely underestimated
and not generally mentioned in pathology reports.
We performed a histopathological concordance study among 15 dedicated and non-
dedicated genito-urinary pathologists on 116 histological slides containing prostate
atrophic lesions, PIN and cancer.
Powered by Editorial Manager® and ProduXion Manager® from Aries Systems Corporation
We found an overall percent agreement between all possible pairs of reviewers of
80.2% for prostate cancer, 67% for PIN, and 48.7% for any atrophic changes. When
we designated a genitourinary pathologist single gold standard, the mean percent
agreement increased: 96.6% for prostate cancer, 91.7% for PIN, 71.9% for PAH.
According to the raising relevance of PAH in prostate cancer our results on
histopathological concordance support the inclusion of at least PAH in the routine
pathology reporting of pathological prostate specimens.
Response to Reviewers: Reviewer #1: Giunchi et al describe the interobserver variability of the diagnosis of
atrophic lesions of the prostate, PIN and prostate cancer. Compared to previous
studies, the current study uses real glass slides and includes both malignant and
benign lesions. This may be of some interest but there are several problems with the
paper.
We thank the reviewer for the appreciation of our work.
1. Two uropathologists selected the slides but the gold standard seems to be based on
the assessment of one of them. Who was used as gold standard? Was his gold
standard diagnosis unbiased by the other colleague? Or did the two expert
pathologists discuss the cases in an open discussion? Did he first decide the gold
standard and then a selection was done by the two of them together or vice versa? If
the selection was done first it must be difficult to avoid discussing the diagnosis. This
would influence their diagnoses and affect the results of the reproducibility study.
As stated in the Methods section the cases were selected by two dedicated uro-
pathologists (EB and MF) from two different institutions, Each pathologist was blinded
to the other’s evaluation and they did not discuss the cases. The gold standard was
another GU pathologist (RM) from a third institution who did not participate in case
selection.  For comparison, we also present data for the overall percentage agreement,
which would not be as heavily dependent on the evaluation by a single reviewer.
2. 120 slides were selected including biopsies, RPs, TURPs. How many of each? Why
are there only 115 and 116 cases, respectively in Tab 1?  Were all cases circulated
among 30 pathologists? Did you use recuts? How many sets?
The two pathologists who selected the cases asked for the re-cutting of three copies of
each selected block. Then they drew circles around 121 areas of interests with a
bullpen in 61 histological slides. The three sets of slides were then circulated among
the 15 pathologists who accepted to join the study. One pathologist did not review 5
cases leaving 116 cases for the analysis of prostate cancer. Another pathologist did
not review 1 case for some types of inflammation/atrophy, and two cases for other
types of inflammation/atrophy, leaving either 114 or 115 cases for those analyses. We
have now added this information in the Methods section.
3. Which pathologists participated? The panel had 15 members but there are 11
institutions in the author list. This indicates that some work in the same department.
Should be specified as it may affect the results.
The 15 pathologists belonged to 9 institutions since other centers participated just for
the statistical analyses. Slides were circulated blindly and each pathologist provided
separate review files to the statisticians who completed the statistical analyses. This
was made possible since 6 and 2 pathologists respectively belonged to the two
institutions that were in charge of case selection.
4. There should be a Table where the gold standard diagnoses are compared to the
results of the other pathologists. I.e. for each diagnostic entity the number of gold
standard diagnoses (i.e. the total number of cases) should be given and then the
summarized results of the other panelists.
5. There is no information about how the panelists voted, only percentages of
agreement and kappas.
6. How was the performance of individual pathologists? The 15 panel members could
be summarized in a Table.
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We attempted to compile all of the individual reviews in one table but ultimately
decided that it would be too complicated to be readily interpretatble. Therefore we have
decided to add to the existing table another two columns for the agreement among the
GU and non GU dedicated pathologist with the gold standard.
7. How was the histopath characteristics of the cancers? Grade? Extent? It may be
very easy to recognize cancer vs atrophy. Were cancers selected with an emphasis on
difficult cases, e.g. cancer of atrophic type.
The purpose of the study was not the inter-rater agreement on prostate cancer. Apart
from the circled atrophic lesions we have asked to the reviewers to check and report
the presence of cancer in the 61 slides and to provide Gleason’s score according to
the 2005 criteria that were the up-to-date classification at that time. Cancer areas were
not circled and there were random tumors with variable Gleason score but all with
conventional acinar morphology.
8. Were any of the patients treated with hormones or radiotherapy?
None of the patients was treated with hormone ablation or radiation therapy. This
information is now included in the Methods section.
9. The first statement in the Introduction is that long term inflammation is an important
aetiology factor in PCa. This is still hypothetical. The link between inflam and cancer is
theoretically interesting but so far it has little practical relevance. Chronic inflammation
and atrophy is almost ubiquitous in middle aged and elderly men. There is no evidence
that it would have clinical relevance to report these lesions. No recommendations have
been issued that these patients should be followed or treated in a different way that
any other man with a PSA elevation and non-symptomatic benign biopsies. It would
change the game considerably if such recommendations were issued and convincing
studies would be needed. The authors are therefore recommended to express their
views in a much more cautious way.
10. I disagree with the main conclusion that the results support the inclusion of PAH in
the diagnosis. Just because a diagnosis is reproducible this does not mean that it is
clinically relevant. Different sorts of atrophy may be seen in a large number of elderly
men and has no clinical importance as far as we know today. It may be relevant to
mention e.g. PAH in a report just to make sure that it is documented and a pathologist
in a referral center would see that the lesion has been observed and interpreted as
benign. The statement in the abstract that atrophy and inflammation is underestimated
is misleading. They may very well be observed but many pathologists consider that
they are not relevant to report.
We agree with the reviewer that the link between histological inflammatory lesions and
prostate cancer is not yet demonstrated. However, we are enforced to disagree with
the reviewer on the direct link between inflammation and prostate cancer that is
supported by mounting evidence in the literature. A search on Pubmed for
“inflammation and prostate cancer” yields 2104 papers and most of them are related to
infections, dietary habits and metabolic diseases inducing higher inflammation
regardless of age. Histological inflammatory changes are not generally described in
pathology reports except for acute or granulomatous inflammation. This is peculiar
compared to many other organs were chronic inflammation is consistently reported and
it is related to various risks (i.e. in the stomach or in the liver). The main goal of the
present paper is to sensitize the pathology audience to the relevance of inflammation
in prostate cancer and the potential correlations to histology that could be
demonstrated only after widespread implementation of this nomenclature in the
pathology reports.
11. Some linguistic revision is needed
The manuscript has been proof-read by the native English speaking co-authors
Reviewer #2: In this sudy, Giunchi and co-workers evaluated the diagnostic
concordance of several bening and malignant prostatic lesions, with emphasis on
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atrophic lesions, among 15 Pathologists, some of then especially dedicated to GU tract
Pathology. They found that overall agreement was "fair" for PAH and partial atrophy,
whereas it was strong to almost perfect for PIN and prostate carcinoma. Results
improved when a single gold standard GU tract Pathologist was designated. In this
setting, the concordance rating did not significantly differed between GU Pathologists
and Non-GU Pathologists. Based on these findings, the authors propose that a
statement on PAH/PIA should be included in standard pathology reporting of all
prostate specimens.
Globally, this is na interesting study that adds to the published literature on diagnostic
concordance on prostate pathology. Nevertheless, some issues require clarification.
We thank the reviewer for the appreciation of our work
Major issues:
1. The diagnostic problems in prostatic pathology (as well as in other organs) are
different according to specimen under analysis, i.e., diagnosing prostate cancer, PIN or
atrophic lesions in biopsy is a quite different challenge than in prostatectomy
specimens. As the study lumped together diagnosis in biopsies, radical
prostatectomies and TURPs, it is not clear whether specimen type influenced the
results. Thus, not only the number of cases  but also the concordance statistics for
each type of specimen should be provided.
The type of sample actually could not effect the analysis. In fact, the two pathologists
who selected the cases drew circles around 120 areas of interests with atrophic lesions
with a bullpen in 61 histological slides. We requested to the 15 pathologists who
accepted to join the study to score just the areas of interest except for checking the
entire slide in case of prostate cancer and PIN. We have now added this information in
the Methods section.
2. Apparently, diagnoses were based on HE stained slides, only. Nevertheless, it is
widely accepted that adequate immunostains are a valuable ancillary technique for
differential diagnosis among prostate cancer, PIN and atrophic lesions in challenging
cases. Please indicate why immunostaning was not included.
Since the areas of interest with atrophic lesions were already circled in the slides we
have decided to send for review just the H&E.
3. It is somewhat confusing that concordance increased when a "gold standard" was
set for comparison (Method 2). This seems counterintuitive. Could the authors provide
an explanation for the source of variation in Method 1 compared to Method 2?
The first method considers all possible pairs of reviewers and then computes the
average agreement between all of those possible pairs. This method produces lower
percent agreement because all of the reviewers, whether they correctly or incorrectly
identified a particular lesion type, are compared to each other. The misclassification of
lesion types is compounded in this analysis, but it has the advantage of not relying
heavily on the evaluation of a single reviewer. In contrast, the second method
compares the scoring to a single rater. This rater was selected because of his
expertise in the field and is likely to misclassify lesions less frequently than the other
reviewers. Therefore, this analysis more closely reflects the percent agreement with
the “true” lesion type.
4. The similar results observed for concordance among GU dedicated and non-GU
dedicated Pathologists is also surprising, considering previous publications on the
diagnostic concordance between expert Uropathologists vs. community-based
Pathologists. How do the authors explain this homogeneity of results?
We agree with the reviewer on this issue. A possible explanation is that the
pathologists selected for the study were recruited in medical centers with considerable
workload of GU pathology in the routine practice. Another possible reason could be
related to circling of the areas of interest that might have guided the reviewer. We have
now added a sentence about this in the study limitations part of the Discussion.
5. It should be made clearer why reporting PAH/PIA could improve patient care and in
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which setting (prostate biopsy for prostare cancer suspects?). How would this impact
patient management?
We agree with the reviewer that currently there is no direct evidence of the
predictive/prognostic role of PIA/PAH. However, the direct link between inflammation
and prostate cancer is supported by mounting evidence in the literature. A search on
Pubmed for “inflammation and prostate cancer” yields 2104 papers and most of them
are related to infections, dietary habits and metabolic diseases inducing higher
inflammation. Histological inflammatory changes are not generally described in
pathology reports except for acute or granulomatous inflammation. This is peculiar
compared to many other organs were chronic inflammation is consistently reported and
it is related to various risks (i.e. in the stomach or in the liver). The main goal of the
present paper is to sensitize the pathology audience to the relevance of inflammation
in prostate cancer and the potential correlations to histology that could be
demonstrated only after widespread implementation of this nomenclature in the
pathology reports.
Minor issues:
1. Abstract, line 3: should read "...widely underestimated and generally not
mentioned..."
2. Page 4, line 7: should read "...1990s..."
3. Page 5, line 2: should read "(SACF)" instead of "(PACF)"
4. Page 5, line 7: should read "...found that 83% of atrophic lesions..."
5. Page 5, line 59: please add the designation of the kappa category 0.61-0.80
Thank you. We made the corrections.
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Reviewer #1: Giunchi et al describe the interobserver variability of the diagnosis of atrophic lesions of the 
prostate, PIN and prostate cancer. Compared to previous studies, the current study uses real glass slides 
and includes both malignant and benign lesions. This may be of some interest but there are several 
problems with the paper.  
 
We thank the reviewer for the appreciation of our work. 
 
1. Two uropathologists selected the slides but the gold standard seems to be based on the assessment of 
one of them. Who was used as gold standard? Was his gold standard diagnosis unbiased by the other 
colleague? Or did the two expert pathologists discuss the cases in an open discussion? Did he first decide the 
gold standard and then a selection was done by the two of them together or vice versa? If the selection was 
done first it must be difficult to avoid discussing the diagnosis. This would influence their diagnoses and 
affect the results of the reproducibility study. 
As stated in the Methods section the cases were selected by two dedicated uro-pathologists (EB and MF) 
from two different institutions, Each pathologist was blinded to the other’s evaluation and they did not 
discuss the cases. The gold standard was another GU pathologist (RM) from a third institution who did not 
participate in case selection.  For comparison, we also present data for the overall percentage agreement, 
which would not be as heavily dependent on the evaluation by a single reviewer. 
 
2. 120 slides were selected including biopsies, RPs, TURPs. How many of each? Why are there only 115 and 
116 cases, respectively in Tab 1?  Were all cases circulated among 30 pathologists? Did you use recuts? How 
many sets?  
The two pathologists who selected the cases asked for the re-cutting of three copies of each selected block. 
Then they drew circles around 121 areas of interests with a bullpen in 61 histological slides. The three sets 
of slides were then circulated among the 15 pathologists who accepted to join the study. One pathologist 
did not review 5 cases leaving 116 cases for the analysis of prostate cancer. Another pathologist did not 
review 1 case for some types of inflammation/atrophy, and two cases for other types of 
inflammation/atrophy, leaving either 114 or 115 cases for those analyses. We have now added this 
information in the Methods section. 
 
3. Which pathologists participated? The panel had 15 members but there are 11 institutions in the author 
list. This indicates that some work in the same department. Should be specified as it may affect the results.  
The 15 pathologists belonged to 9 institutions since other centers participated just for the statistical 
analyses. Slides were circulated blindly and each pathologist provided separate review files to the 
statisticians who completed the statistical analyses. This was made possible since 6 and 2 pathologists 
respectively belonged to the two institutions that were in charge of case selection. 
 
4. There should be a Table where the gold standard diagnoses are compared to the results of the other 
pathologists. I.e. for each diagnostic entity the number of gold standard diagnoses (i.e. the total number of 
cases) should be given and then the summarized results of the other panelists.  
Authors Click here to download Authors' Response to Reviewers'
Comments Giunchi et al.point by point_JRR.docx
 5. There is no information about how the panelists voted, only percentages of agreement and kappas.  
 
6. How was the performance of individual pathologists? The 15 panel members could be summarized in a 
Table.  
 
We attempted to compile all of the individual reviews in one table but ultimately decided that it would be 
too complicated to be readily interpretatble. Therefore we have decided to add to the existing table 
another two columns for the agreement among the GU and non GU dedicated pathologist with the gold 
standard. 
 
7. How was the histopath characteristics of the cancers? Grade? Extent? It may be very easy to recognize 
cancer vs atrophy. Were cancers selected with an emphasis on difficult cases, e.g. cancer of atrophic type.  
The purpose of the study was not the inter-rater agreement on prostate cancer. Apart from the circled 
atrophic lesions we have asked to the reviewers to check and report the presence of cancer in the 61 slides 
and to provide Gleason’s score according to the 2005 criteria that were the up-to-date classification at that 
time. Cancer areas were not circled and there were random tumors with variable Gleason score but all with 
conventional acinar morphology. 
 
8. Were any of the patients treated with hormones or radiotherapy?  
None of the patients was treated with hormone ablation or radiation therapy. This information is now 
included in the Methods section. 
 
9. The first statement in the Introduction is that long term inflammation is an important aetiology factor in 
PCa. This is still hypothetical. The link between inflam and cancer is theoretically interesting but so far it has 
little practical relevance. Chronic inflammation and atrophy is almost ubiquitous in middle aged and elderly 
men. There is no evidence that it would have clinical relevance to report these lesions. No recommendations 
have been issued that these patients should be followed or treated in a different way that any other man 
with a PSA elevation and non-symptomatic benign biopsies. It would change the game considerably if such 
recommendations were issued and convincing studies would be needed. The authors are therefore 
recommended to express their views in a much more cautious way.  
10. I disagree with the main conclusion that the results support the inclusion of PAH in the diagnosis. Just 
because a diagnosis is reproducible this does not mean that it is clinically relevant. Different sorts of atrophy 
may be seen in a large number of elderly men and has no clinical importance as far as we know today. It 
may be relevant to mention e.g. PAH in a report just to make sure that it is documented and a pathologist in 
a referral center would see that the lesion has been observed and interpreted as benign. The statement in 
the abstract that atrophy and inflammation is underestimated is misleading. They may very well be 
observed but many pathologists consider that they are not relevant to report.   
We agree with the reviewer that the link between histological inflammatory lesions and prostate cancer is 
not yet demonstrated. However, we are enforced to disagree with the reviewer on the direct link between 
inflammation and prostate cancer that is supported by mounting evidence in the literature. A search on 
Pubmed for “inflammation and prostate cancer” yields 2104 papers and most of them are related to 
infections, dietary habits and metabolic diseases inducing higher inflammation regardless of age. 
Histological inflammatory changes are not generally described in pathology reports except for acute or 
granulomatous inflammation. This is peculiar compared to many other organs were chronic inflammation is 
consistently reported and it is related to various risks (i.e. in the stomach or in the liver). The main goal of 
the present paper is to sensitize the pathology audience to the relevance of inflammation in prostate 
cancer and the potential correlations to histology that could be demonstrated only after widespread 
implementation of this nomenclature in the pathology reports. 
 
11. Some linguistic revision is needed 
The manuscript has been proof-read by the native English speaking co-authors 
 
 
Reviewer #2: In this sudy, Giunchi and co-workers evaluated the diagnostic concordance of several bening 
and malignant prostatic lesions, with emphasis on atrophic lesions, among 15 Pathologists, some of then 
especially dedicated to GU tract Pathology. They found that overall agreement was "fair" for PAH and 
partial atrophy, whereas it was strong to almost perfect for PIN and prostate carcinoma. Results improved 
when a single gold standard GU tract Pathologist was designated. In this setting, the concordance rating did 
not significantly differed between GU Pathologists and Non-GU Pathologists. Based on these findings, the 
authors propose that a statement on PAH/PIA should be included in standard pathology reporting of all 
prostate specimens. 
Globally, this is na interesting study that adds to the published literature on diagnostic concordance on 
prostate pathology. Nevertheless, some issues require clarification. 
We thank the reviewer for the appreciation of our work 
 
Major issues: 
1. The diagnostic problems in prostatic pathology (as well as in other organs) are different according to 
specimen under analysis, i.e., diagnosing prostate cancer, PIN or atrophic lesions in biopsy is a quite 
different challenge than in prostatectomy specimens. As the study lumped together diagnosis in biopsies, 
radical prostatectomies and TURPs, it is not clear whether specimen type influenced the results. Thus, not 
only the number of cases  but also the concordance statistics for each type of specimen should be provided. 
The type of sample actually could not effect the analysis. In fact, the two pathologists who selected the 
cases drew circles around 120 areas of interests with atrophic lesions with a bullpen in 61 histological 
slides. We requested to the 15 pathologists who accepted to join the study to score just the areas of 
interest except for checking the entire slide in case of prostate cancer and PIN. We have now added this 
information in the Methods section. 
 
2. Apparently, diagnoses were based on HE stained slides, only. Nevertheless, it is widely accepted that 
adequate immunostains are a valuable ancillary technique for differential diagnosis among prostate cancer, 
PIN and atrophic lesions in challenging cases. Please indicate why immunostaning was not included. 
Since the areas of interest with atrophic lesions were already circled in the slides we have decided to send 
for review just the H&E. 
 3. It is somewhat confusing that concordance increased when a "gold standard" was set for comparison 
(Method 2). This seems counterintuitive. Could the authors provide an explanation for the source of 
variation in Method 1 compared to Method 2? 
The first method considers all possible pairs of reviewers and then computes the average agreement 
between all of those possible pairs. This method produces lower percent agreement because all of the 
reviewers, whether they correctly or incorrectly identified a particular lesion type, are compared to each 
other. The misclassification of lesion types is compounded in this analysis, but it has the advantage of not 
relying heavily on the evaluation of a single reviewer. In contrast, the second method compares the scoring 
to a single rater. This rater was selected because of his expertise in the field and is likely to misclassify 
lesions less frequently than the other reviewers. Therefore, this analysis more closely reflects the percent 
agreement with the “true” lesion type. 
 
4. The similar results observed for concordance among GU dedicated and non-GU dedicated Pathologists is 
also surprising, considering previous publications on the diagnostic concordance between expert 
Uropathologists vs. community-based Pathologists. How do the authors explain this homogeneity of results? 
We agree with the reviewer on this issue. A possible explanation is that the pathologists selected for the 
study were recruited in medical centers with considerable workload of GU pathology in the routine 
practice. Another possible reason could be related to circling of the areas of interest that might have 
guided the reviewer. We have now added a sentence about this in the study limitations part of the 
Discussion.  
 
5. It should be made clearer why reporting PAH/PIA could improve patient care and in which setting 
(prostate biopsy for prostare cancer suspects?). How would this impact patient management? 
We agree with the reviewer that currently there is no direct evidence of the predictive/prognostic role of 
PIA/PAH. However, the direct link between inflammation and prostate cancer is supported by mounting 
evidence in the literature. A search on Pubmed for “inflammation and prostate cancer” yields 2104 papers 
and most of them are related to infections, dietary habits and metabolic diseases inducing higher 
inflammation. Histological inflammatory changes are not generally described in pathology reports except 
for acute or granulomatous inflammation. This is peculiar compared to many other organs were chronic 
inflammation is consistently reported and it is related to various risks (i.e. in the stomach or in the liver). 
The main goal of the present paper is to sensitize the pathology audience to the relevance of inflammation 
in prostate cancer and the potential correlations to histology that could be demonstrated only after 
widespread implementation of this nomenclature in the pathology reports. 
 
 
Minor issues: 
1. Abstract, line 3: should read "...widely underestimated and generally not mentioned..." 
2. Page 4, line 7: should read "...1990s..." 
3. Page 5, line 2: should read "(SACF)" instead of "(PACF)" 
4. Page 5, line 7: should read "...found that 83% of atrophic lesions..." 
5. Page 5, line 59: please add the designation of the kappa category 0.61-0.80 
Thank you. We made the corrections. 
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Abstract: 
Epidemiological and biological evidence indicate a causal relationship between the presence of proliferative 
atrophic lesions (PAH), the development of PIN and prostate cancer. Inflammatory and atrophic lesions of 
the prostate are widely underestimated and not generally mentioned in pathology reports.  
We performed a histopathological concordance study among 15 dedicated and non-dedicated genito-
urinary pathologists on 116 histological slides containing prostate atrophic lesions, PIN and cancer. 
We found an overall percent agreement between all possible pairs of reviewers of 80.2% for prostate 
cancer, 67% for PIN, and 48.7% for any atrophic changes. When we designated a genitourinary pathologist 
single gold standard, the mean percent agreement increased: 96.6% for prostate cancer, 91.7% for PIN, 
71.9% for PAH. 
According to the raising relevance of PAH in prostate cancer our results on histopathological concordance 
support the inclusion of at least PAH in the routine pathology reporting of pathological prostate specimens. 
 
Key words: Atrophic lesions, Inflammation, PAH, Prostate. 
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Introduction: 
Long-term chronic inflammation is linked to the development of carcinoma in several organ systems and it 
is also an important aetiology factor in prostate cancer (PCa). [1] Based on observations in other organs 
such as the stomach, liver and large bowel in the 1990s, the interest in inflammatory and atrophic lesions in 
prostate cancer was further cultivated. Inflammatory cells could produce cellular or genomic irreversible 
damage in prostate cells; cause loss of tolerance to normal prostate antigens; and induce an autoimmune 
self-perpetuating reaction leading in turn to a “field effect” for the development of PCa  [2]. The major 
events potentially leading to prostate inflammation are infections (virus, fungi, mycobacteria and parasite, 
and rarely bacteria), hormonal alteration, physical trauma, urine reflux and dietary habits.  These exposures 
can result in injury to the luminal cell layer, which in turn induces reactive (defensive) hyperplasia of basal 
cells called “proliferative inflammatory atrophy” (PIA), thereby initiating genetic instability. Cytokines 
released by the inflammatory cells slowly induce epithelial proliferation and angiogenesis with the 
accumulation of genomic changes, eventually resulting in neoplastic transformation through PIN (prostatic 
intraepithelial neoplasia). [1] Several studies have referred to a morphological transition between PIA and 
PIN, as well as PIA and prostate cancer. These observations are further supported by evidence of an 
elevated proliferative fraction in atrophic areas and the closely proximity of these regions to PIN and 
PCa.[3, 4] In addition somatic genomic alterations detectable in PIN and PCa have been found in cells in PIA. 
In particular, these cells show molecular effects of inflammatory stress, such as high levels of glutathione S- 
transferase P1 (GSTP1), GSTA1 and cyclooxygenase-2 (COX-2). [2] 
 
Prostatic inflammation and atrophy are not routinely collected as part of a standard histopathologic review, 
yet there is considerable interest in the potential role of atrophy and inflammation in the development and 
progression of prostate cancer. Recent studies have related the presence of prostatic atrophic lesions and 
inflammation to prostate cancer risk [5, 6, 7, 8] and survival [9], with mixed results. One possible 
explanation for the inconsistent findings is misclassification of the various lesion types due to subjectivity in 
grading. 
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The increasing correlation among inflammation, atrophic lesions, PIN and PCa led De Marzo et al. to 
propose a histological classification of the different atrophic lesions in 4 morphological patterns: simple 
atrophy (SA), partial atrophy (PA), post atrophic hyperplasia (PAH) and simple athropy with cyst formation 
(SACF). PAH can be considered a surrogate of PIA. While other studies have shown that PIN is frequently 
overdiagnosed in pathological specimens [10], the reliability of the assessment of inflammation and 
atrophic changes is unclear. A concordance study found that 83% of atrophic lesions were classified as the 
correct subtype, but there was substantial variability in accuracy across specific lesion types [11]. To 
specifically address this gap in the literature, we undertook a histopathological concordance study that 
focused on inflammation, atrophy, PIN and cancer among 15 European pathologists, including both those 
dedicated and non-dedicated to genitourinary pathology. 
 
Materials and Methods: 
Two dedicated uropathologists (MF, EB) selected 61 slides of prostate tissue and identified 121 areas of 
interests (ROIs) with inflammation, atrophic lesions, PIN and PCa on the basis of the original pathology 
report from biopsies, radical prostatectomy and TURP specimens. The slides were selected from the 
Pathology archives at the S. Orsola-Malpighi Hospital in Bologna and the S. Luigi Gonzaga Hospital in Turin. 
None of the included patients was treated with hormone ablation or radiation therapy. Specifically, the two 
pathologists who selected the cases asked for the re-cutting of three copies of each selected block. Then 
they drew circles around the area of interests with a bullpen. The three sets of slides were anonymized and 
circulated among the 15 pathologists who accepted to join the study for histological revision of prostate 
atrophic lesions according to the De Marzo et al. classification, [11]. Twenty-one of the 61 slides included at 
least a single focus of PCa together with atrophic lesions. Of the 30 pathologists originally invited to the 
study, 15 professionals from 9 centers accepted to review the slides and completed the evaluation form. 
Eight of these 15 pathologists were dedicated experienced uropathologists while 7 were general 
pathologists. Participating pathologists were asked to independently record the presence of the following 
histological features: prostate cancer, PIN, SA, SACF, PAH/PIA, PA, acute prostatitis, and chronic prostatitis. 
Two of the uropathologists did not review all of slides for all lesion types, leaving 116 slides for analysis of 
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prostate cancer, 115 for most types of inflammation and atrophy, and 114 for simple atrophy with cyst 
formation. . The entire review process took about two years.  
 
Statistical Methods 
We used two methods to evaluate the interpreter reliability of each histological feature. First we 
considered the overall percentage agreement, which is the average percent agreement across all possible 
rater pairs. We also estimated kappa statistics, which range from -1 to 1, where 1 indicates perfect 
agreement, 0 represents the agreement expected by chance, and values <0 indicate less agreement than is 
expected by chance. A suggested interpretation of kappa is that 0.21-0.40 is fair agreement, 0.41-0.60 is 
moderate agreement, and 0.61-0.99 is almost perfect agreement. The exact kappa coefficient was 
developed because it reduces to Cohen’s un-weighted Kappa for two raters. Second, we used the rating of 
one particularly experienced dedicated genitourinary pathologist (RM) as the “gold standard” by which to 
compare all other raters. We calculated the mean percentage agreement and mean Cohen’s Kappa across 
the 15 pairs. Comparisons were made among all 15 pathologists, and the subset of dedicated GU 
pathologists (N=8).  
 
Results: 
Table 1 shows that the overall percent agreement between all possible pairs of reviewers was 80.2% for 
prostate cancer, 67% for PIN, and 48.7% for any atrophic changes. While the kappa statistics for prostate 
cancer indicated nearly perfect agreement, agreement for PIN and atrophic changes were in the fair to 
moderate range. When specific types of focal prostatic atrophy were considered, the overall percentage 
agreement ranged from 5.2% for SA to 43% for SACF, all with kappa statistics indicating modest precision. 
In particular the agreement for PAH and partial atrophy was similar and low: 26.1% and 22.6% respectively. 
The average agreement between pairs of raters was 20% for chronic inflammation and 53% for acute 
inflammation. 
 When a single gold standard genitourinary pathologist was designated, the mean percent 
agreement increased: 96.6% for prostate cancer (kappa = 0.88) and 91.7% for PIN (kappa=0.55). There was 
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agreement with the gold standard by 92.5% of the raters regarding the presence of any atrophic changes, 
but the kappa statistic indicated that this agreement was often due to chance (kappa=0.47). Simple atrophy 
had the lowest agreement (65.2%), followed by PAH (71.9%), partial atrophy (84.7%), and simple atrophy 
with cyst formation (88.4%). Pathologists agreed with the gold standard rater for chronic and acute 
inflammation in 71.9% and 69.4% of ratings, respectively. The dedicated genitourinary pathologists 
consistently had higher agreement for all lesion types, which was especially pronounced for atrophic 
changes and specific types of focal atrophy. The agreement for atrophic lesions (92.2%) was stratified as 
follows: 86,9% for SACF, 84,6% for PA, 77.4% for PAH and 64.9% for SA. The agreement among non-
genitourinary pathologists with the gold standard was similar to the results for dedicated genitourinary 
pathologists. 
 
Discussion: 
Our current understanding of PIA has raised questions about the role of this lesion in the development of 
prostate cancer. Moreover, the association between chronic inflammation/PAH and prostate cancer 
appears to be stronger compared to the other atrophic lesions such as SA. Nevertheless few studies have 
tested the diagnostic agreement among pathologists for atrophic lesions, which will impact the results of 
studies of this topic and inform the need to conduct centralized pathological reviews. In this study we 
evaluated the ability of general and genitourinary-dedicated pathologists to recognize atrophic lesions 
according to the classification proposed by De Marzo in order to determine whether there is utility in 
introducing the characterization of these lesions into standard pathology reports. Our results highlighted a 
moderate agreement for atrophic lesions among both genitourinary and general pathologists, but with 
patterns that varied by atrophy type. The agreement was favorable for PAH and simple atrophy with cyst 
formation among all the pathologists. However, for PA and SA the concordance was suboptimal. Further 
training on recognizing these lesions types may be warranted. With respect to the diagnosis of prostate 
cancer and PIN, our results confirmed several previous reports that found excellent agreement for cancer 
and very good agreement for PIN.  Our concordance data support the standard reporting of PIN.  
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Our study is affected by several limitations. The number of raters and reviewed cases were both modest. 
However, we estimated that the 121 slides included in the study would allow us to identify differences in 
lesion attribution among the 15 participating pathologists. Other limitations derive from the binary 
categorization of the variables as presence or absence of each histological feature. Had we included in the 
review the extent of inflammation, the concordance findings may have changed. Similarly, we provided the 
reviewers with H&E slides that were already circled for areas of interest to be scored. If areas of interest 
were not indicated, as in real-world clinical and research settings, non GU-dedicated pathologists may have 
underestimated the atrophic lesions. Despite the reference pathologist being the most experienced, the 
reference gold standard was likely imperfect. However, if we selected as the gold standard, for instance, 
the majority opinion of the raters we may have introduced more substantial bias. 
 
This study did not confirm results from other pathology review studies where dedicated genitourinary 
pathologists displayed higher diagnostic concordance for prostate cancer, PIN and atrophic lesions 
compared to general pathologists [12]. In our data, differences in the agreement with the gold standard for 
dedicated and general European pathologist were minimal.  
 
Given the growing interest in inflammation in prostate cancer risk assessment, our results support the 
inclusion of at least PAH/PIA in the standard pathology reporting of all pathological prostate specimens, but 
that some specific types of atrophy and for inflammation, additional training may improve concordance. 
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Table 1. Concordance among 15 pathologists in histological assessment of inflammation, atrophy, PIN and cancer    
  Subjects All pathologists N=15 GU pathologists (N=7) Non-GU pathologists (N=8) GU pathologists (N=7) 
Vs gold standard 
Non-GU pathologists 
(N=8) Vs gold standard 
All pathologists (N=15) 
Vs gold standard 
Overall % 
agreement 
Exact kappa Average % 
agreement 
Average 
Cohen’s 
Kappa 
Average % 
agreement 
Average 
Cohen’s 
Kappa 
Average % 
agreement 
Average 
Cohen’s 
Kappa 
Average % 
agreement 
Average 
Cohen’s 
Kappa 
Average % 
agreement 
Average 
Cohen’s 
Kappa 
Acute 
inflammation 
115 53.0% 0.34 70.0% 0.31 68.8% 0.28 70,0% 0,305 68,8% 0,276 69.4% 0.42 
Chronic 
inflammation 
115 20.0% 0.36 72.5% 0.46 71.5% 0.45 72,5% 0,456 71,5% 0,447 71.9% 0.46 
Atrophic 
changes 
115 48.7% 0.32 92.2% 0.30 89.1% 0.36 92,2% 0,298 89,1% 0,362 90.6% 0.47 
PAH 115 26.1% 0.42 77.4% 0.44 79.6% 0.42 77,4% 0,442 79,6% 0,420 71.9% 0.55 
Partial atrophy 115 22.6% 0.21 84.6% 0.23 84.7% 0.15 84,6% 0,231 84,7% 0,148 84.7% 0.39 
Simple atrophy 115 5.22% 0.22 64.9% 0.22 65.5% 0.25 64,9% 0,221 65,5% 0,251 65.2% 0.38 
Simple atrophy 
with cyst 
formation 
114 43.0% 0.42 86.9% 0.57 89.8% 0.58 86,9% 0,567 89,8% 0,576 88.4% 0.59 
PIN 115 67.0% 0.42 92.9% 0.44 90.7% 0.42 92,9% 0,435 90,7% 0,422 91.7% 0.55 
Prostate cancer 116 80.2% 0.84 96.9% 0.89 96.3% 0.87 96,9% 0,888 96,3% 0,866 96.6% 0.88 
 
 
Figure Legend: Figure  A) Morphological patterns of the focal prostate atrophic lesions: partial atrophy (PA), simple atrophy with cyst formation (SACF), post-atrophic 
hyperplasia (PAH) and simple atrophy (SA) (H&E, 100x magnification). B) Morphological pathway of progression of prostate cancer development through simple atrophy, PAH 
and PIN (H&E, 100x magnification).  
Table Legend: Table 1. Condorance among 15 pathologists in histological assessment of inflammation, atrophy, PIN and cancer 
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